Roivant Sciences Ltd. (ROIV) Shareholders & Insider Trades
Roivant Sciences shareholders at a glance
The largest holder of Roivant Sciences stock is Dexcel Ltd., with 102.8 million shares (14.24% of the company), worth about $3.56 billion as of September 25, 2026. The 10 largest holders together own 55.6%.
In Q2 2026, 526 institutional holdings reports listed 584.0 million shares worth $20.50 billion, up 10.0% in shares from Q1 2026.
Insiders reported 49 transactions in the last two years: 18 sales worth $141.87 million and 1 purchase. The newest one on file is from November 7, 2025 (Venker Eric, Chief Executive Officer).
Major holders as of September 25, 2026; quarterly totals from institutional holdings reports (latest Q2 2026); insider transactions on file through November 7, 2025.
Roivant Sciences Ltd.
Shareholders Summary
2026Q2
Ownership by Type
Geographic Distribution
Largest Roivant Sciences shareholders
| Holder | Shares | % of company | Value |
|---|---|---|---|
| Dexcel Ltd. | 102.8 million | 14.24% | $3.6B |
| Fidelity Management & Research Co. LLC | 81.0 million | 11.22% | $2.8B |
| BlackRock Advisors LLC | 45.0 million | 6.23% | $1.6B |
| Morgan Stanley Investment Management, Inc. | 42.6 million | 5.90% | $1.5B |
| Vivek Ramaswamy3.535 % | 25.5 million | 3.54% | $885.0M |
| QVT Financial LP | 23.7 million | 3.28% | $822.0M |
| Vanguard Capital Management LLC | 22.1 million | 3.06% | $766.0M |
| Vanguard Portfolio Management LLC | 21.6 million | 3.00% | $750.0M |
| Mayukh Sukhatme2.579 % | 18.6 million | 2.58% | $645.0M |
| Goldman Sachs Wealth Services LP | 18.6 million | 2.57% | $643.0M |
As of September 25, 2026.
Roivant Sciences institutional holdings by quarter
| Quarter | Reports | Shares | Value |
|---|---|---|---|
| Q2 2026 | 526 | 584.0 million | $20.5B |
| Q1 2026 | 473 | 531.0 million | $14.7B |
| Q4 2025 | 428 | 509.0 million | $11.0B |
| Q3 2025 | 370 | 503.0 million | $7.6B |
| Q2 2025 | 362 | 516.0 million | $5.8B |
| Q1 2025 | 334 | 558.0 million | $5.6B |
| Q4 2024 | 339 | 563.0 million | $6.7B |
| Q3 2024 | 317 | 572.0 million | $6.6B |
Shares and value held by institutions that file quarterly holdings reports (options not included).
Roivant Sciences insider trades
| Insider | Date | Title | Transaction | Value |
|---|---|---|---|---|
| Venker Eric | Nov 7, 2025 | Chief Executive Officer | Sale at price 20.22 per share. | $4.0M |
| Venker Eric | Nov 7, 2025 | Chief Executive Officer | Conversion of Exercise of derivative security at price 3.85 per share. | $770,000 |
| Momtazee James C | Oct 20, 2025 | Director | Stock Award(Grant) at price 0.00 per share. | – |
| Oren Ilan | Oct 20, 2025 | Director | Stock Award(Grant) at price 0.00 per share. | – |
| Epperly Melissa B | Oct 20, 2025 | Director | Stock Award(Grant) at price 0.00 per share. | – |
| Venker Eric | Oct 17, 2025 | Chief Executive Officer | Sale at price 16.93 - 17.06 per share. | $14.5M |
| Venker Eric | Oct 17, 2025 | Chief Executive Officer | Conversion of Exercise of derivative security at price 15.85 per share. | $13.5M |
| Venker Eric | Oct 8, 2025 | Chief Executive Officer | Sale at price 16.15 - 16.34 per share. | $10.8M |
| Venker Eric | Oct 8, 2025 | Chief Executive Officer | Conversion of Exercise of derivative security at price 3.85 - 15.85 per share. | $6.0M |
| Venker Eric | Sep 23, 2025 | Chief Executive Officer | Sale at price 14.83 - 15.01 per share. | $25.5M |
| Venker Eric | Sep 22, 2025 | Chief Executive Officer | Conversion of Exercise of derivative security at price 3.85 per share. | $6.0M |
| Gline Matthew | Sep 18, 2025 | Chief Executive Officer | Purchase at price 15.07 per share. | $49,957 |
Newest 12 of 49 insider transactions in the last two years.
Questions and answers
Who owns the most Roivant Sciences stock?
Dexcel Ltd., with 14.24% of the company (as of September 25, 2026). Next: Fidelity Management & Research Co. LLC (11.22%) and BlackRock Advisors LLC (6.23%).
How many institutions own Roivant Sciences stock?
526 institutional holdings reports listed Roivant Sciences shares in Q2 2026, 584.0 million shares in all worth $20.50 billion.
Are Roivant Sciences insiders buying or selling the stock?
In the last two years insiders reported 18 sales and 1 purchase (49 transactions in all); the newest on file is from November 7, 2025.
